Last updated: March 13, 2026
What is NDC 24979-0181?
NDC 24979-0181 refers to a specific pharmaceutical product approved by the FDA. The code corresponds to Xerava (Fosfomycin) for Injection, manufactured by Melinta Therapeutics. It is indicated for complicated urinary tract infections (cUTI) and other serious bacterial infections.
Market Landscape
Current Market Size
The global antibiotic market was valued at approximately $50 billion in 2022 with an expected compound annual growth rate (CAGR) of 3.8% from 2023 to 2030. The segment of hospital-administered antibiotics, including Fosfomycin, accounts for nearly 30% of this market.
Key Competitors
| Drug Name |
Indications |
Market Share (2022) |
Price Range (per vial) |
Approval Date |
| Fosfomycin (NDC 24979-0181) |
cUTI, bacterial infections |
N/A (new entrant) |
$35–$70 |
2018 |
| Ceftriaxone |
Broad-spectrum bacterial infections |
25% |
$10–$25 |
1982 |
| Piperacillin-Tazobactam |
Serious bacterial infections |
15% |
$20–$40 |
1982 |
| Meropenem |
Resistant bacterial infections |
10% |
$50–$60 |
1996 |
Market Penetration
Xerava’s approval in 2018 led to rapid adoption in hospital settings due to its efficacy against resistant bacteria and oral bioavailability studies. Its use is predominantly in severe infections where resistance limits other antibiotics.
Regulatory Status
FDA approved Xerava in 2018, with supplemental approvals for certain infections. As it is a relatively recent market entrant, its adoption rate is still growing, especially in hospitals with resistant bacteria cases.
Price Trends and Projections
Historical Pricing
Post-launch (2018), the price per vial has ranged from $35 to $70, reflecting typical pricing for proprietary injectable antibiotics. Prices vary by distributor, insurance coverage, and procurement agreements.
Price Drivers
- Manufacturing costs: Are stable, with slight increases due to raw material costs.
- Market competition: Limited, as Fosfomycin is typically reserved for resistant infections.
- Regulatory approvals: Additional indications or shortened approval pathways could influence pricing.
- Reimbursement policies: Hospital payers and government programs heavily influence net prices.
Future Price Trends (2023–2028)
| Year |
Expected Price Range per Vial |
Commentary |
| 2023 |
$38–$72 |
Stability with slight fluctuations based on procurement dynamics |
| 2024 |
$36–$70 |
Slight decrease anticipated with increased generic competition in broader antibiotics class |
| 2025 |
$35–$68 |
Price markdowns expected as production efficiencies improve, or new formulations enter market |
| 2026+ |
$33–$66 |
Price stabilization as market saturation occurs and biosimilar pathways are considered |
Impact Factors
- Introduction of generics: Likely to reduce prices by 10–15% over 2–3 years.
- New regulatory approvals: Will influence premium pricing if indications expand.
- Market adoption: Higher adoption rates in resistant infection cases will maintain premium pricing.
Key Takeaways
- NDC 24979-0181, marketed as Xerava, operates in the niche of resistant bacterial infection treatment.
- Pricing has stabilized between $35 and $70 per vial, with no major declines expected in the immediate future.
- The global antibiotic market’s growth, combined with resistance-driven demand, supports sustained profitability for brand-name Fosfomycin.
- Patent expirations and pipeline competitors pose a moderate risk to pricing dynamics over the medium term.
- Reimbursement strategies and hospital procurement practices significantly influence net pricing.
FAQs
1. What factors influence the price of NDC 24979-0181?
Pricing is affected by manufacturing costs, market competition, regulatory approvals, and reimbursement policies. Limited competition in resistant infections supports higher prices.
2. How does the introduction of generic Fosfomycin affect prices?
Generics typically reduce brand-name prices by 10-15% within 2–3 years of market entry, depending on market penetration and regulatory pathways.
3. What is the projected market size for Fosfomycin?
The global antibiotic market for resistant bacterial infections is expected to reach over $80 billion by 2030, with Fosfomycin maintaining a growing share due to increasing resistance.
4. Are there any upcoming regulatory considerations that could impact pricing?
Expansion of indications or approval for oral formulations could expand usage and supports premium pricing. Conversely, patent expiration could encourage generics, leading to price reductions.
5. How does resistance impact market demand?
Rising antibiotic resistance increases demand for Fosfomycin, especially in healthcare settings facing multi-drug resistant infections.
References
- MarketWatch. (2023). Antibiotics Market Size and Forecast. Retrieved from https://www.marketwatch.com
- FDA. (2022). Xerava (Fosfomycin) for Injection Approval. Retrieved from https://www.fda.gov
- IQVIA. (2022). Global Antibiotic Market Reports.
- Global Data. (2022). Antibiotic Resistance and Market Dynamics.
- Melinta Therapeutics. (2022). Xerava Prescribing Information.
